Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
First Claim
1. A method of treating ocular hypertension which comprises administering to a mammal having ocular hypertension a therapeutically effective amount of a compound represented by formula II:
0 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to the use of derivatives of F-type prostaglandins as ocular hypotensives. The PGF derivatives used in accordance with the invention are represented by the following formula I:
wherein wavy line attachments indicate either the alpha (α) or beta (β) configuration; dashed bonds represent a double bond, or a single bond, R is a substituted heteroaryl radical, R1 is hydrogen or a lower alkyl radical having up to six carbon atoms, X is selected from the group consisting of —OR1, —N(R1)2, R1 is hydrogen or a lower alkyl radical having up to six carbon 20 atoms, X is selected from the group consisting of —OR1, —N(R1)2 and —N(R5)SO2R6, wherein R5 represents hydrogen or CH2OR6 and R6 represents hydrogen or a lower alkyl radical having up to six carbon atoms and halogen substituted derivatives of said lower alkyl radical, e.g. a fluoro substituted lower alkyl radical; Y is ═O or represents 2 hydrogen radicals. Certain of the compounds represented by Formula I comprise another aspect of the present invention.
-
Citations
7 Claims
- 1. A method of treating ocular hypertension which comprises administering to a mammal having ocular hypertension a therapeutically effective amount of a compound represented by formula II:
- 4. A method of treating glaucoma which comprises administering to a mammal having glaucoma a therapeutically effective amount of a compound represented by formula I:
- 6. A method of treating elevated intraocular pressure which comprises administering to a mammal having elevated intraocular pressure a therapeutically effective amount of a compound represented by formula I:
Specification